Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2020.07.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Efficacy and Adverse Events of Low-Dose Intravesical BCG Therapy for Non-Muscle-Invasive Bladder Cancer].
Hinyokika Kiyo
December 2024
The Department of Urology, Morinomiya Hospital.
We examined the efficacy and adverse effects of low-dose intravesical Bacillus Calmette-Guérin (BCG) therapy in patients with non-muscle-invasive bladder cancer. Patients who underwent intravesical BCG therapy (n＝176 ; 198 courses) at our hospital between April 2012 and December 2022 were enrolled. After assigning patients to either the low-dose or regular-dose (40 or 80 mg of BCG Tokyo 172 strain) groups, treatment efficacy and incidence of adverse events were compared.
View Article and Find Full Text PDFManagement of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle Invasive Bladder Cancer.
Curr Urol Rep
January 2025
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Article Synopsis
- The review discusses current treatment methods and strategies for managing lower urinary tract symptoms (LUTS) linked to treatments like transurethral resection and intravesical therapy.
- Recent findings highlight that while there's limited research, some oral agents and new therapies show promise in alleviating LUTS associated with intravesical treatments, such as phenazopyridine and beta-3 agonists.
- The review emphasizes the need for more research to validate these treatments and to develop effective strategies for managing LUTS in patients undergoing various intravesical therapy regimens.
High-dose intravenous BCG vaccination induces enhanced immune signaling in the airways.
Sci Adv
January 2025
Department of Biological Engineering, MIT, Cambridge, MA, USA.
Intradermal Bacillus Calmette-Guérin (BCG) is the most widely administered vaccine, but it does not sufficiently protect adults against pulmonary tuberculosis. Recent studies in nonhuman primates show that intravenous BCG administration offers superior protection against (). We used single-cell analysis of bronchoalveolar lavage cells from rhesus macaques vaccinated via different routes and doses of BCG to identify alterations in the immune ecosystem in the airway following vaccination.
View Article and Find Full Text PDFHumoral correlate of vaccine-mediated protection from tuberculosis identified in humans and non-human primates.
bioRxiv
December 2024
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Development of an effective tuberculosis (TB) vaccine has been challenged by incomplete understanding of specific factors that provide protection against (Mtb) and the lack of a known correlate of protection (CoP). Using a combination of samples from a vaccine showing efficacy (DarDar [NCT00052195]) and Bacille Calmette-Guerin (BCG)-immunized humans and nonhuman primates (NHP), we identify a humoral CoP that translates across species and vaccine regimens. Antibodies specific to the DarDar vaccine strain () sonicate (MOS) correlate with protection from the efficacy endpoint of definite TB.
View Article and Find Full Text PDFThe Impact of Health Information System Interventions on Maternal and Child Health Service Utilizations in Ethiopia: A Quasi-Experimental Study.
Glob Health Sci Pract
December 2024
JSI Research & Training Institute, Inc., Ethiopia Data Use Partnership, Addis Ababa, Ethiopia.
Background: Health information systems (HIS) are vital in supporting all aspects of managing health systems, financing, policymaking, and service delivery. A package of priority HIS interventions was piloted in selected woredas across all regions in Ethiopia. This study examined the impact of HIS interventions on maternal and child health (MCH) service utilization.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!